CRISPR Medicine

Century Therapeutics

Main focus: Next-generation cell therapies for the treatment of cancer

Company stage: Pre-clinical

Diseases (gene editing): Cancer

Genome editing tool: CRISPR-MAD7

Funding stage: Public (NASDAQ:IPSC)

Location: Philadelphia, PA, USA

Website: https://www.centurytx.com/

Pipeline: https://www.centurytx.com/pipeline

Gene-editing partnerships: Inscripta, Bristol Myers Squibb


Century Therapeutics is developing next-generation cell-based therapies to treat haematological and solid tumours. The company uses its iPSC platform to generate allogeneic, iPSC-derived natural killer (NK) and T cell products. The company uses the CRISPR-MAD7 system to introduce multiple knock-outs to its cellular products, in order to avoid host-versus-graft reactions and increase persistence and durability.

See the full view ...